Vaxxas
Cambridge, United States · Biotechnology · 127 employees
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
Funding history
- Funding Round — $90.0M — Aug 2025
- Funding Round — $23.0M — Dec 2022
Recent signals
- Jan 07, 2026: Vaxxas Appoints David Peacock as Chief Executive Officer
- Aug 25, 2025: Raised $90.0M
- Jan 13, 2025: Vaxxas Named Concept Stage Winner of United States’ BARDA Prize for Advancing Microarray Patches for Vaccination
- Oct 28, 2024: Launched Vaxxas Secures License for Next-Generation RSV Vaccine from NIH to Innovate Needle-Free Vaccination.
- Jun 05, 2023: Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
- Dec 05, 2022: Raised $23.0M
See plans & pricing → Track Vaxxas’s funding, hiring, and signals — with verified contacts — on Fundz.